Stock data
| Market cap. | £100.7m |
| Last close | 181.50p |
| High / Low (52 weeks) | 188.0p / 134.2p |
| Stock market listing | LSE |
| Forecast net debt (m) | N/A |
| Forecast gearing ratio (%) | N/A |
| Team | Investment Companies & Trusts |
| Sector | Investment Trusts |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | 1.4 | (2.68) | 18.24 |
| Relative * | 6.38 | 5.31 | 29.94 |
* % Relative to local index
Other companies covered in sector
Latest research
Quoted portfolio continues to outperform
Review | Investment Trusts | 16/04/2012
Improved fee structure
Review | Investment Trusts | 25/10/2011
Quoted and unquoted biotech exposure
Review | Investment Trusts | 07/04/2011
Recovery potential
QuickView | Investment Trusts | 03/11/2010
Investment summary
International Biotechnology Trust’s (IBT) quoted portfolio has, for the past three years, outperformed the NASDAQ Biotechnology Index. Although the unquoted portfolio (c 16%) has been a drag on overall performance, it is reaching maturity and may provide uplifts on exit, as reflected in the 2011 sale of Cadent to Align Technologies at 3.1x the carrying book value. The manager reports that exit conditions have improved significantly during the past six months, and currently expects five to six actions per year for the next two years, with further events in 2014/15.
Last updated on 16/04/2012
Key management
| Alan Clifton, Chairman |
| Kate Bingham, Fund manager |
| David Pinniger, Fund manager |
Company address
| 71 Kingsway London WC2B 6ST United Kingdom View website |
